Responses
Regular and Young Investigator Award Abstracts
Immuno-Conjugates and Chimeric Molecules
1190 A novel ‘2+1’bispecific T cell engager platform, enables enhanced anti-tumor activity with reduced risk of CRS
Compose a Response to This Article
Other responses
No responses have been published for this article.
